Ying Pan antibody Endoscopic molecular imaging of human bladder cancer using a CD 47

, 260ra148 (2014); 6 Sci Transl Med et al. Ying Pan antibody Endoscopic molecular imaging of human bladder cancer using a CD47 Editor's Summary imaging approach to diagnosing various bladder cancers will translate after further optimization. administration of a fluorescent antibody and the use of already available clinical tools, it is hoped that this molecular a diagnostic challenge for white light imaging. Because this approach only requires topical −− carcinoma in situ lesions authors reported a sensitivity of 82.9% and a specificity of 90.5%. They further correctly identified five of six patients. Overall, 119 bladder regions were analyzed using the fluorescent antibody and blue light cystoscopy. The instilled into human bladders with muscle and nonmuscle invasive cancer that had been recently removed from authors attached a brightly fluorescent tag, called a quantum dot, to a CD47 antibody. The fluorescent antibody was targeted the cancer-specific marker CD47 that is present on the surface of solid tumors, including in the bladder. The et al. based imaging that looks for superficial tissue changes, such as color and texture. To this end, Pan − light Molecular imaging of bladder cancer could greatly improve on current methods of diagnosis, which rely on white Lighting Up Bladder Cancer Lesions

[1]  Sanjiv S. Gambhir,et al.  Endoscopic molecular imaging of human bladder cancer using a CD47 antibody , 2014, Science Translational Medicine.

[2]  Mithat Gönen,et al.  Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe , 2014, Science Translational Medicine.

[3]  Xavier Paoletti,et al.  EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype , 2014, Science Translational Medicine.

[4]  Dieter Jocham,et al.  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. , 2013, European urology.

[5]  R. Tsien,et al.  Fluorescence-guided surgery with live molecular navigation — a new cutting edge , 2013, Nature Reviews Cancer.

[6]  M. Swihart,et al.  Nanotoxicity Assessment of Quantum Dots: From Cellular to Primate Studies , 2013 .

[7]  Thomas D. Wang,et al.  Targeted Imaging of Esophageal Neoplasia with a Fluorescently Labeled Peptide: First-in-Human Results , 2013, Science Translational Medicine.

[8]  T. Griffiths Current perspectives in bladder cancer management , 2013, International journal of clinical practice.

[9]  M. Swihart,et al.  Nanotoxicity assessment of quantum dots: from cellular to primate studies. , 2013, Chemical Society reviews.

[10]  Joseph C Liao,et al.  New optical imaging technologies for bladder cancer: considerations and perspectives. , 2012, The Journal of urology.

[11]  Maximilian Burger,et al.  Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. , 2012, The Journal of urology.

[12]  Rui Hu,et al.  A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. , 2012, Nature nanotechnology.

[13]  Sanjiv S Gambhir,et al.  A molecular imaging primer: modalities, imaging agents, and applications. , 2012, Physiological reviews.

[14]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[15]  R. China,et al.  The CD 47-signal regulatory protein alpha ( SIRPa ) interaction is a therapeutic target for human solid tumors , 2012 .

[16]  J. Carlsson Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors , 2012, Tumor Biology.

[17]  A. Beck,et al.  Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy , 2011 .

[18]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[19]  A. Ray,et al.  Epidermal growth factor receptor expression in urinary bladder cancer , 2011, Indian journal of urology : IJU : journal of the Urological Society of India.

[20]  W. Kassouf,et al.  Update on the management of non-muscle invasive bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[21]  H. Grossman,et al.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. , 2010, The Journal of urology.

[22]  C. Cordon-Cardo,et al.  Molecular pathways of urothelial development and bladder tumorigenesis. , 2010, Urologic oncology.

[23]  F. Salazar,et al.  An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  M. Schwaiger,et al.  Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice , 2009, Journal of Nuclear Medicine.

[25]  Joseph C Liao,et al.  Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. , 2009, The Journal of urology.

[26]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[27]  R. Montironi,et al.  Immunohistochemical Expression of Prostate Stem Cell Antigen in Cystoprostatectomies with Incidental Prostate Cancer , 2009, International journal of immunopathology and pharmacology.

[28]  Mahul B Amin,et al.  Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications , 2009, Modern Pathology.

[29]  Thomas D. Wang,et al.  Fibered confocal microscopy of bladder tumors: an ex vivo study. , 2009, Journal of endourology.

[30]  Robert Tibshirani,et al.  Boolean implication networks derived from large scale, whole genome microarray datasets , 2008, Genome Biology.

[31]  Christopher H Contag,et al.  Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. , 2008, Nature medicine.

[32]  S. Brandau,et al.  Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  Debashis Sahoo,et al.  Extracting binary signals from microarray time-course data , 2007, Nucleic acids research.

[34]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[35]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Liang Cheng,et al.  Bladder cancer: epidemiology, staging and grading, and diagnosis. , 2005, Urology.

[37]  T. Tzai,et al.  Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Zhennan Gu,et al.  Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. , 2001, Cancer research.

[39]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.